Losmapimod in Chronic Obstructive Pulmonary Disease Patients Stratified by Fibrinogen. (EVOLUTION)

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborators:
Technology Strategy Board
GlaxoSmithKline
Royal Brompton & Harefield NHS Foundation Trust
University of Cambridge
Information provided by (Responsible Party):
Dr Ian B Wilkinson, Cambridge University Hospitals NHS Foundation Trust
ClinicalTrials.gov Identifier:
NCT01541852
First received: February 20, 2012
Last updated: July 22, 2014
Last verified: July 2014
  Purpose

The main purpose of this study is to determine the effect of Losmapimod on blood vessels in patients with Chronic Obstructive Pulmonary Disease (COPD). Although COPD is a lung disease, it is also associated with an increased risk of cardiovascular disease (e.g. heart attacks and stroke). The investigators believe that this is a result of inflammation within the body, which damages the lining (endothelium) and walls of blood vessels. These changes can promote the development of fatty deposits within the walls of arteries (atherosclerosis) which can rupture and block arteries causing damage.


Condition Intervention Phase
Chronic Obstructive Pulmonary Disease
Drug: Losmapimod
Drug: Placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Prevention
Official Title: An Evaluation Of Losmapimod in Patients With Chronic Obstructive Pulmonary Disease (COPD) With Systemic Inflammation Stratified Using Fibrinogen (EVOLUTION)

Resource links provided by NLM:


Further study details as provided by Cambridge University Hospitals NHS Foundation Trust:

Primary Outcome Measures:
  • Vascular inflammation on FDG PET-CT [ Time Frame: Days 0 to Day 112 ] [ Designated as safety issue: No ]
    To determine the effect of Losmapimod in COPD patients on vascular structure and function as assessed by the change in Vascular inflammation as measured by FDG PET-CT

  • Endothelial function as measured by flow mediated dilatation [ Time Frame: Days 0 to Day 112 ] [ Designated as safety issue: No ]
    To determine the effect of Losmapimod in COPD patients on vascular structure and function as assessed by the change in endothelial function as measured by flow mediated dilatation

  • Arterial structure and plaque characteristics on MRI [ Time Frame: Days 0 to Day 112 ] [ Designated as safety issue: No ]
    To determine the effect of Losmapimod in COPD patients on vascular structure and function as assessed by the change in arterial structure and plaque characteristics as measured by MRI (MRI is an optional sub-study and analysis will be based on a sufficient number of datasets).


Secondary Outcome Measures:
  • Lung inflammation on FDG PET-CT [ Time Frame: Days 0 to 112 ] [ Designated as safety issue: No ]
    To determine the effects of Losmapimod on the change in inflammation in lung tissue as assessed by FDG PET-CT

  • Fat inflammation on FDG PET-CT [ Time Frame: Days 0 to 112 ] [ Designated as safety issue: No ]
    To determine the effects of Losmapimod on the change in fat inflammation as assessed by FDG PET-CT

  • Arterial stiffness as measured by arterial tonometry [ Time Frame: Days 0 to 112 ] [ Designated as safety issue: No ]
    To determine the effects of Losmapimod on the change in arterial stiffness as measured by arterial tonometry

  • Blood biomarkers of systemic inflammation (Fibrinogen and high sensitivity CRP) [ Time Frame: Days 0 to 112 ] [ Designated as safety issue: No ]
    To determine the effects of Losmapimod on the change in blood biomarkers of inflammation such as Fibrinogen and high sensitivity CRP

  • Indices of lung function (6 minute walk test and sniff nasal inspiratory pressure) [ Time Frame: Days 0 to 112 ] [ Designated as safety issue: No ]
    To determine the effects of Losmapimod on the change in indices of lung function and physical performance as measured by 6 minute walk test and sniff nasal inspiratory pressure

  • Body composition and fat as assessed by Free fat mass index [ Time Frame: Days 0 to 112 ] [ Designated as safety issue: No ]
    To determine the effects of Losmapimod on the change in body composition and fat as measured by Free fat mass index

  • Number of adverse events as a measure of safety and tolerability [ Time Frame: Days 0 to 112 ] [ Designated as safety issue: No ]
    To determine the effects of Losmapimod on the number of adverse events as a measure of safety and tolerability


Estimated Enrollment: 60
Study Start Date: June 2012
Estimated Study Completion Date: September 2014
Primary Completion Date: February 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Losmapimod
7.5mg tablet twice daily
Drug: Losmapimod
One tablet of Losmapimod 7.5mg twice daily
Other Name: GW856553
Placebo Comparator: Placebo
One tablet twice daily
Drug: Placebo
One tablet twice daily
Other Name: Lactose Monohydrate

Detailed Description:

The study aims to enrol sufficient COPD subjects (stratified by fibrinogen level) so that 60 patients complete the study. Study patients will have a 50% chance of receiving either Losmapimod or Placebo. Patients will be expected to attend for up to 12 visits, over a 24 week period. The visits consist of an initial screening visit, and 2 pre-dose imaging visits to include a PET-CT scan and an optional MRI scan. The next 7 visits (at 2-4 weekly intervals) involve blood tests and safety evaluations. A number of procedures including heart tracings (ECGs), non-invasive vascular measurements and lung function tests at the start and at the end of the study. Repeat imaging with PET-CT and MRI will be performed at the end of the study and a follow-up visit.

The purpose of the study is to see if the study medication has a beneficial effect on vascular function and structure. It is envisaged that this trial will help define more evolutionary biomarkers to focus on to help COPD patients in the future.

  Eligibility

Ages Eligible for Study:   50 Years to 85 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Male or female patients between 50 and 85 years of age inclusive at screening, with a body weight ≥ 45 kg and BMI ≤35 kg/m2.
  2. Patients with a clinical diagnosis of COPD with GOLD Stages 1, 2, 3 or 4, or GOLD-U.
  3. Patient has FEV1/FVC < 0.7 post-bronchodilator.
  4. Patient is a smoker or an ex-smoker with a smoking history of at least 10 pack years (1 pack year = 20 cigarettes smoked per day for 1 year or equivalent).
  5. Baseline fibrinogen value of >2.8 g/L (Klauss method)
  6. ALT < 2xULN at screening; alkaline phosphatase and bilirubin > 1.5xULN at screening (isolated bilirubin >1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin <35%).
  7. Patients must have a QTc <450 msec on screening (V1) ECG (using average value of triplicate ECGs). For patients with complete Right bundle branch block, the QTc must be <480msec on Screening V1 ECG. Patients with other ECG findings will be excluded if warranted at the discretion of the CI/PI. QTc readings will be QTcF.
  8. Patients who fulfil local imaging centre requirements will be enrolled.

Exclusion Criteria:

The presence of any of the following will preclude patient inclusion:

  1. Inability in the opinion of the PI to provide Informed Consent.
  2. A cardiovascular event in the last 6 months (i.e. acute coronary syndrome, unstable angina, CABG, PCI, stroke, MI, carotid endarterectomy).
  3. Patients on daunorubicin, doxorubicin, topotecan, mitoxantrone.
  4. Previous lung reduction surgery.
  5. Patients with known clinically significant pulmonary diagnoses in which inflammation is thought to play a role including diagnosis of bronchiectasis, sarcoidosis, lung fibrosis, interstitial lung disease, or α1-antitrypsin deficiency.
  6. A positive pre-trial Hepatitis B surface antigen or positive Hepatitis C antibody result within 3 months of screening.
  7. Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).
  8. Patients with known chronic infections such as HIV or known active tuberculosis.
  9. Patients with rheumatoid arthritis, connective tissue disorders and other conditions known to be associated with active chronic inflammation (e.g. Inflammatory Bowel Disease).
  10. Insulin controlled Type 1 or Type 2 diabetics.
  11. Diabetics on oral hypoglycaemics/diet with HbA1c (DCCT) > 8% (OR HbA1c (IFCC) > 64 mmol/mol), at screening. [note: fasting glucose to be checked again at first FDG-PET/CT scan, and if glucose > 11mmol/L at that visit, patients will be excluded from trial]
  12. Participation in a previous research trial in the last 3 years which involved exposure to significant ionising radiation (i.e. cumulative research radiation dose >5 mSv)
  13. History of malignancy within the past 5 years (with the exception of localized carcinoma of the skin that has been resected for cure).
  14. Previous exposure to Losmapimod.
  15. Patients who have donated more than 500 mL of blood within 2 months prior to the trial medication administration, Visit 3 (Day 1).
  16. Participation in a clinical trial where the patient has received a drug or new chemical entity within 30 days or 5 half-lives, or twice the duration of the biological effect of the drug (whichever is longer) prior to the first dose of trial medication, Visit 3 (Day 1).
  17. History of alcohol/drug abuse or dependence within 6 months of the trial, Screening Visit 1 (Day -45 to -14).
  18. Women of childbearing potential are excluded from this trial.
  19. Any medical history or clinically relevant abnormality that is deemed by the principal investigator and/or medical monitor to make the patient ineligible for inclusion because of a safety concern.
  20. Use of systemic corticosteroids (oral or IV) 4 weeks prior to Visit 2 (Day -14 to -1).
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01541852

Locations
United Kingdom
Cambridge University Hospitals NHS Foundation Trust
Cambridge, Cambridgeshire, United Kingdom, CB2 0QQ
Royal Brompton & Harefield NHS Foundation Trust
London, United Kingdom, SW3 6NP
Sponsors and Collaborators
Cambridge University Hospitals NHS Foundation Trust
Technology Strategy Board
GlaxoSmithKline
Royal Brompton & Harefield NHS Foundation Trust
University of Cambridge
Investigators
Principal Investigator: Joseph Cheriyan, MD Cambridge University Hospitals
Principal Investigator: Michael Polkey, MD Royal Brompton & Harefield Foundation NHS Trust
  More Information

No publications provided

Responsible Party: Dr Ian B Wilkinson, Reader & Hon. Consultant Physician, Clinical Pharmacology/GIM, Cambridge University Hospitals NHS Foundation Trust
ClinicalTrials.gov Identifier: NCT01541852     History of Changes
Other Study ID Numbers: A092519, 2011-004936-75
Study First Received: February 20, 2012
Last Updated: July 22, 2014
Health Authority: United Kingdom: Medicines and Healthcare Products Regulatory Agency
United Kingdom: Administration of Radioactive Substances Advisory Committee

Keywords provided by Cambridge University Hospitals NHS Foundation Trust:
Vascular Inflammation
FDG PET-CT
COPD
Atherosclerosis
p38 MAP kinase inhibitor

Additional relevant MeSH terms:
Inflammation
Lung Diseases
Pulmonary Disease, Chronic Obstructive
Lung Diseases, Obstructive
Pathologic Processes
Respiratory Tract Diseases

ClinicalTrials.gov processed this record on August 28, 2014